Glycycoumarin Exerts Anti-Liver Cancer Activity by Directly Targeting T-LAK Cell-Originated Protein Kinase

Xinhua Song,Shutao Yin,Enxiang Zhang,Lihong Fan,Min Ye,Yong Zhang,Hongbo Hu
DOI: https://doi.org/10.18632/oncotarget.11610
2016-01-01
Oncotarget
Abstract:Glycycoumarin (GCM) is a major bioactive coumarin compound isolated from licorice and the anti-cancer activity of GCM has not been scientifically addressed. In the present study, we have tested the anti-liver cancer activity of GCM using both in vitro and in vivo models and found for the first time that GCM possesses a potent activity against liver cancer evidenced by cell growth inhibition and apoptosis induction in vitro and tumor reduction in vivo. Mechanistically, GCM was able to bind to and inactivate oncogenic kinase T-LAK cell-originated protein kinase (TOPK), which in turn led to activation of p53 pathway. Our findings supported GCM as a novel active compound that contributed to the anti-cancer activity of licorice and TOPK could be an effective target for hepatocellular carcinoma (HCC) treatment.
What problem does this paper attempt to address?